PR Newswire Asia's news > Biotechnology

 < Previous page   |   Title only   |   Print    Next page > 
     
ArkBio's RSV Antiviral Drug Ziresovir Receives FDA Approval for Phase II Clinical Trial
SHANGHAI , Aug. 14, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the U.S. Food and Drug Administration (FDA) has approved ziresovir (AK0529) ...
2026-08-14T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Innorna Nominated for 2026 Prix Galien USA Best Startup Award
HONG KONG SAR, China and SHENZHEN, China and CAMBRIDGE, Mass. , Aug. 13, 2026 /PRNewswire/ -- Innorna, a clinical-stage biotech company advancing RNA medicines, today announced that it has been nominated ...
2026-08-13T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Mervyn's Petcare Marks One Year at Magnify Incubator on UCLA campus with Launch of Second Feline Supplement on Amazon
SEOUL, South Korea , Aug. 13, 2026 /PRNewswire/ -- Ari's Purrfect Omega+Multivitamin Lickable Supplement expands the Feline First product line as Yuyu Pharma's U.S. pet subsidiary approaches a full ...
2026-08-13T    Biotechnology 
Axtria to Build Industry's Largest Pharma-Specific AI Engineering Team, Scaling to 1,000 by December 2026
NEW DELHI , Aug. 13, 2026 /PRNewswire/ --  Axtria Inc. ,  a global leader in AI-first data analytics solutions for the life sciences industry, today announced plans to expand its Forward Deployed ...
2026-08-13T    Biotechnology   Computer Software   Computer/Electronics   Health Care/Hospital 
/DISREGARD RELEASE: IASO Bio/
We are advised by IASO Bio that journalists and other readers should disregard the news release, IASO Biotechnology Announces Acquisition of Singapore-Based Cell Therapy Company MediSix Therapeutics, issued ...
2026-08-13T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Accro Bioscience to Present Phase Ib Data of AC-101, an Oral Selective RIPK2 Inhibitor, for Moderate-to-Severe UC at UEG Week 2026 in Barcelona
NEW YORK and SUZHOU, China , Aug. 13, 2026 /PRNewswire/ -- Accro Bioscience, a clinical-stage biotechnology company pioneering the development of novel therapeutics for immune mediated diseases, ...
2026-08-13T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Nobel Heroes Day 2026 - AI For Science Summit (AFSS) Launches in Singapore This October
Focusing on AI for Science: Nobel Laureates and Global Capital Explore the Frontiers of Scientific Innovation ...
2026-08-13T    Biotechnology   Computer/Electronics   Education   Health Care/Hospital 
ArkBio Announces China IND Approval for its Antiviral Drug-Fc Conjugate (AFC) Candidate AK0406 for Influenza Prophylaxis
SHANGHAI , Aug. 13, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the Investigational New Drug (IND) application for AK0406 injection, the company's ...
2026-08-13T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Bringing K-Aesthetics to Australia: PharmaResearch Showcases REJURAN® at Aesthetics 2026
Following REJURAN ® 's TGA approval in 2023, the company hosted scientific sessions and a clinical masterclass for Australian healthcare professionals. ...
2026-08-13T    Biotechnology   Cosmetics & Personal Care   Medical Equipment   Medical/Pharmaceuticals 
PanTRKare™ Officially Approved as the Companion Diagnostic for VELMARTO® (Eratrectinib)
NANJING, China , Aug. 12, 2026 /PRNewswire/ -- August 6,  the NMPA granted approval to Geneseeq's PanTRKare™ NTRK1/2/3 Gene Fusion Detection Kit as a companion diagnostic for VELMARTO ® ...
2026-08-12T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
 < Previous page    Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.